A recent metformin study casts doubts on longevity indications
A new retrospective study contradicts previous evidence of metformin’s potential effects on lifespan extension in a general population, but for real answers, randomized trials are needed.
In 2014, a retrospective study was published by Bannister et al . which laid the foundation for metformin – traditionally a first-line treatment for type II diabetes – to be regarded as a potential “anti-aging” drug for the general population. The authors of the U.K.-based study reported that diabetic patients on metformin monotherapy were found to have lower mortality than non-diabetic controls, despite the obvious baseline health bias favoring the control group. This remarkable finding suggests that this drug has benefits for lifespan beyond management of diabetes – benefits which could impr
related reading
- Longevity FAQ - Laura Demingldeming.com
- Metformin and Its Benefits for Various Diseasesncbi.nlm.nih.gov
- Nintil - The Longevity FAQnintil.com
- The development and benefits of metformin in various diseaseslink.springer.com
- What we wish we knew entering the aging fieldlibrariesforthefuture.bio
- Nintil - Beyond lifespan as a metric in aging research: why reprogramming is promisingnintil.com
- Six ways metabolic health affects longevity | Levels | Levelslevelshealth.com
- Milky Eggs >> Blog Archive >> Lifespan extension: separating fact from fictionmilkyeggs.com
- Eliminating Distractions in Longevity Researchcremieux.xyz
- Why Does Ozempic Cure All Diseases?astralcodexten.com
- Fig. 1: Proposed mechanisms for metformin-induced reductions in blood levels of glucose. | Nature Reviews Endocrinologynature.com
- My Plan to Slow Down Aging - Richard Hanania's Newsletterrichardhanania.com